^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Breast Cancer Index®

    Company:
    Hologic
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    BCI is an RT-PCR assay on FFPE breast tumor tissue integrating two biomarkers: (1) HOXB13:IL17BR ratio (H/I) assessing endocrine responsiveness, and (2) Molecular Grade Index (MGI) from five proliferation genes. Evaluates 11 genes total (7 informational + 4 reference). Indicated for HR+, HER2-, LN- or LN+ (1-3 nodes) early-stage invasive breast cancer. Provides: quantitative late (post-5yr) and overall (0-10yr) distant recurrence risk, plus prediction of extended endocrine therapy benefit.
    Cancer:
    Breast Cancer
    Gene:
    BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B), CENPA (Centromere protein A), HOXB13 (Homeobox B13), IL17RB (Interleukin 17 Receptor B), NEK2 (NIMA Related Kinase 2), RACGAP1 (Rac GTPase activating protein 1)
    See More ...
    Method:
    RT-PCR
    Confirmatory trial(s)
    NSABP B-42
    ,
    NCT00382070
    |
    ASCO 2021